2186 Stock Overview
An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2186 from our risk checks.
Luye Pharma Group Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.87 |
52 Week High | HK$4.00 |
52 Week Low | HK$2.34 |
Beta | 0.78 |
11 Month Change | -1.37% |
3 Month Change | -3.69% |
1 Year Change | -10.87% |
33 Year Change | -33.26% |
5 Year Change | -46.85% |
Change since IPO | -57.16% |
Recent News & Updates
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Recent updates
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?
Feb 29Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S
Jan 09Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Nov 24Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Aug 17Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook
Apr 06Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares
Mar 17A Closer Look At Luye Pharma Group Ltd.'s (HKG:2186) Impressive ROE
Feb 19Shareholder Returns
2186 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 5.5% | -0.9% | -2.8% |
1Y | -10.9% | -0.8% | -6.7% |
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned -0.8% over the past year.
Return vs Market: 2186 underperformed the Hong Kong Market which returned -6.7% over the past year.
Price Volatility
2186 volatility | |
---|---|
2186 Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2186 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2186's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 5,270 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
2186 fundamental statistics | |
---|---|
Market cap | HK$10.27b |
Earnings (TTM) | HK$581.72m |
Revenue (TTM) | HK$6.71b |
18.6x
P/E Ratio1.6x
P/S RatioIs 2186 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2186 income statement (TTM) | |
---|---|
Revenue | CN¥6.14b |
Cost of Revenue | CN¥1.94b |
Gross Profit | CN¥4.20b |
Other Expenses | CN¥3.67b |
Earnings | CN¥532.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.14 |
Gross Margin | 68.44% |
Net Profit Margin | 8.67% |
Debt/Equity Ratio | 61.7% |
How did 2186 perform over the long term?
See historical performance and comparison